GlassScriptPhysician profile
Desmond Levin
NPI 1730178807
$1,874.33
in general payments reported to CMS, 2019-2025
21 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $159 · 2021: $45.82 · 2022: $248 · 2023: $220 · 2024: $340 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $383.72 | 2022-2025 | |
| Amgen INC. | $182.13 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $174.16 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $171.94 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $128.42 | 2023-2025 | Camzyos, Eliquis |
| Abiomed | $99.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $85.13 | 2024-2025 | Evkeeza |
| Abbott Laboratories | $82.07 | 2019-2023 | Jot Dx |
| Cvrx, INC. | $81.47 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $72.49 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $72.42 | 2019-2024 | |
| Medtronic, INC. | $70.62 | 2022-2025 | Attain Command + Surevalve, Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.12 | 2022-2024 | Lifevest |
| Bardy Diagnostics, INC. | $55.27 | 2020-2022 | |
| Chiesi USA, INC. | $40.27 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $25.75 | 2022 | |
| Cardiovascular Systems INC. | $23.46 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.99 | 2022 | |
| Medtronic Vascular, INC. | $16.81 | 2019 | |
| Scpharmaceuticals INC. | $16.69 | 2025 | |
| Esperion Therapeutics, INC. | $15.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desmond Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.